Health-economic implications of the onset of action of antimanic agents

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 13, 1996, Pages 13-18

  Keck Jr , Paul E ^a   McElroy, Susan L ^a   Bennett, Jerry A ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LITHIUM; VALPROIC ACID;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; HEALTH ECONOMICS; HUMAN; MANIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BIPOLAR DISORDER; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HEALTH CARE COSTS; HUMANS; LITHIUM; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 12644290267     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:395-405
2. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271:918-924
3. Keck PE Jr, McElroy SL. Treatment of bipolar disorder with lithium. Psychiatric Annals 1993;23:1-6
4. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
5. Cooper TB, Bergner P-E, Simpson GM. The 24-hour serum lithium level as a prognosticator of dosage requirements. Am J Psychiatry 1973;130: 601-603
6. Cooper TB, Simpson GM. The 24-hour lithium level as a prognosticator of dosage requirements: a 2-year follow-up study. Am J Psychiatry 1976; 133:440-443
7. Kocsis JH, Lieberman KW, Reding GR, et al. High-dose lithium therapy. Biol Psychiatry 1978;13:759-702
8. Mellerup ET, Dam H, Wildschiodtz G, et al. Relation to lithium dose and to plasma peak levels. Acta Psychiatr Scand 1979;60:177-184
9. Gengo F, Timko J, D'Antonio J, et al. Prediction of dosage of lithium carbonate: use of a standard predictive method. J Clin Psychiatry 1980;41: 319-321
10. Tyrer SP, Graf P, Kalvar M, et al. Estimation of lithium dose requirement by lithium clearance, serum lithium and saliva lithium following a loading dose of lithium carbonate. Neuropsychobiology 1981;7:152-158
11. Zetin M, Garber D, Cramer M. A simple mathematical model for predicting lithium dose requirement. J Clin Psychiatry 1983;44:144-145
12. Zetin M, Garber D, De Antonio M, et al. Prediction of lithium dose: a mathematical alternative to the test-dose method. J Clin Psychiatry 1986;47: 175-178
13. Cummings MA, Haviland MG, Cummings KL, et al. Lithium dose prediction: a prospective case series [letter]. J Clin Psychiatry 1988;49:373
14. Markoff RA, King M. Does lithium dose prediction improve treatment efficiency? prospective evaluation of a mathematical method. J Clin Psychopharmacol 1992;12:305-308
15. Cohen IM, Bunney WE Jr, Cole JO, et al. The current status of lithium therapy: report of the APA Task Force. Am J Psychiatry 1975;132:997-1001
16. Bryant SG, Guernsey BG, Hokanson JA, et al. Predicting lithium dose [letter]. J Clin Psychiatry 1984;45:95
17. Johnston JA, Powers DA, Coleman JH, et al. Protocols for the use of psychoactive drugs, part III: protocol for the treatment of bipolar affective disorder with lithium. J Clin Psychiatry 1984;45:210-213
18. Keck PE Jr, Bennett JA, Stanton SP. Health-economic aspects of the treatment of manic-depressive illness with divalproex. Reviews in Contemporary Pharmacotherapy 1995;6:597-604
19. Maj M, Arena F, Lovero N, et al. Factors associated with response in DSM-III major depression and bipolar disorder. Pharmacopsychiatry 1985;18: 309-313
20. Dunner DL, Fieve RR. Clinical factors in lithium prophylaxis failure. Arch Gen Psychiatry 1974;30:229-233
21. Maj M, Pirozzi R, Starace F. Previous pattern of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord 1989; 17:237-241
22. Faedda GL, Baldessarini RJ, Tohen M, et al. Episode sequence of bipolar disorder and response to lithium. Am J Psychiatry 1991;148:1237-1239
23. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am J Psychiatry 1992;149:1633-1644
24. Himmelhoch JM, Mulla D, Neil JF, et al. Incidence and significance of mixed affective states in a bipolar population. Am J Psychiatry 1976;33: 1062-1066
25. Sonne SC, Brady KT, Morion WA. Substance abuse and bipolar affective disorder. J Nerv Ment Dis 1994;182:349-352
26. Reifman A, Wyatt RJ. Lithium: a brake on the rising cost of mental illness. Arch Gen Psychiatry 1980;37:385-388
27. McCreadie RG. The economics of lithium therapy. In: Johnson FN, ed. Depression and Mania: Modern Lithium Therapy. Oxford, England: IRL Press; 1987:257-259
28. Frye MA, Altshuler LL, Szuba MP, et al. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psychiatry 1996;57:17-21
29. Keck PE Jr, Nabulsi AA, Taylor JL, et al. A pharmacoeconomic model of divalproex vs lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 1996;57:213-222
30. Janicak PG, Davis JM, Preskorn SH, et al. Principles and Practice of Psychopharmacotherapy, Baltimore, Md: Williams & Wilkins; 1993
31. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48: 62-68
32. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108-111
33. Keck PE Jr, McElroy SL, Tugrul KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993;54:305-308
34. McElroy SL, Keck PE Jr, Tugrul KC, et al. Valproate as a loading treatment in acute mania. Neuropsychobiology 1993;27:146-149
35. McElroy SL, Keck PE Jr, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-146
36. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-435
37. Andreasen NC. The Scale for Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: University of Iowa; 1984
38. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Treatment of rapid-cycling bipolar disorder with sodium valproate. J Clin Psychopharmacol 1988;8:275-279
39. Calabrese JR, Markovitz PJ, Kimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12(suppl):53S-56S
40. Keck PE Jr, McElroy SL, Strakowski SM, et al. Outcome and comorbidity in first compared with multiple episode mania. J Nerv Ment Dis 1995; 183:320-324
41. McElroy SL, Strakowski SM, Keck PE Jr, et al. Differences and similarities in mixed and pure mania. Compr Psychiatry 1995;36:187-194
42. Keck PE Jr, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992;4:395-405
43. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980;137:782-790
44. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine. Psychopharmacology (Berl) 1979; 66:211-217
45. Grossi E, Sacchetti E, Vita A, et al. Carbamazepine vs chlorpromazine in mania: a double-blind trial. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam, The Netherlands: Excerpta Medica; 1984:177-187
46. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987;48:89-93
47. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915-921
48. Ketter TA, Post RM. Clinical pharmacology and pharmacokinetics of carbamazepine. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in Mood Disorders. New York, NY: Marcel Dekker; 1994:147-188
49. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carbamazepine. Psychiatry Res 1987;21:71-83
50. McElroy SL, Keck PE Jr. Mood disorders: rapid-cycling. In: Dunner D, ed. Current Psychiatric Therapy. Philadelphia, Pa: Saunders; 1993:226-231
51. Nelson HB. Cost effectiveness of carbamazepine in refractory bipolar illness [letter]. Am J Psychiatry 1984;141:465
52. Lipinski JF, Pope HG Jr. Possible synergistic action between carbamazepine and lithium carbonate in the treatment of three acutely manic patients. Am J Psychiatry 1982;139:948-949
53. Nolen WA. Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder. Acta Psychiatr Scand 1983;67:218-225